SRRK241220P17500
- 0.05
- 0.000.00%
Scholar Rock Newsroom
Scholar Rock Price Target Raised to $45 From $36 at Truist
H.C. Wainwright Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $50
Promising Market Dynamics and Growth Potential for Scholar Rock's Apitegromab Boost Buy Rating
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $50
Express News | Scholar Rock Holding Corp : H.c. Wainwright Raises Target Price to $50 From $40
U.S. Small Caps Rise; Scholar Rock Holding Climbs Highest
12 Health Care Stocks Moving In Monday's Pre-Market Session
Sector Update: Health Care Stocks Advance Late Afternoon
Top Midday Gainers
Scholar Rock Hits 3-Year High on Rival Biohaven's Drug Setback
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Biohaven Outcome 'Fundamental Net Positive' for Scholar Rock, Says JPMorgan
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating, Announces Target Price $45
Jefferies Maintains Scholar Rock(SRRK.US) With Buy Rating, Maintains Target Price $50
Why Scholar Rock Shares Are Surging
Scholar Rock Holding Is Maintained at Buy by Truist Securities
Scholar Rock Holding Price Target Raised to $45.00/Share From $36.00 by Truist Securities
Scholar Rock Holding: Strategic Positioning and Pipeline Progress Justify Buy Rating Amid Reduced Competition
Truist Ups Scholar Rock Targets, Calls Potential Takeout Target